Review ArticleREVIEWS AND CONTEMPORARY UPDATES
Gadolinium Deposition in Neurology Clinical Practice
Tyler E. Smith, Andrew Steven and Bridget A. Bagert
Ochsner Journal March 2019, 19 (1) 17-25; DOI: https://doi.org/10.31486/toj.18.0111
Tyler E. Smith
1Department of Neurology, Ochsner Clinic Foundation, New Orleans, LA
MDAndrew Steven
2Department of Radiology, Ochsner Clinic Foundation, New Orleans, LA
3The University of Queensland Faculty of Medicine, Ochsner Clinical School, New Orleans, LA
MDBridget A. Bagert
1Department of Neurology, Ochsner Clinic Foundation, New Orleans, LA
3The University of Queensland Faculty of Medicine, Ochsner Clinical School, New Orleans, LA
MD, MPHREFERENCES
- 1.↵
- 2.↵
- Stojanov DA,
- Aracki-Trenkic A,
- Vojinovic S,
- Benedeto-Stojanov D,
- Ljubisavljevic S
- 3.↵
- 4.↵
- 5.↵
- Kanda T,
- Ishii K,
- Kawaguchi H,
- Kitajima K,
- Takenaka D
- 6.↵
- Robert P,
- Lehericy S,
- Grand S,
- et al.
- 7.↵
- 8.↵
- Murata N,
- Gonzalez-Cuyar LF,
- Murata K,
- et al.
- 9.↵
- Jost G,
- Lenhard DC,
- Sieber MA,
- Lohrke J,
- Frenzel T,
- Pietsch H
- 10.↵
- 11.↵
- 12.↵
- Quattrocchi CC,
- Mallio CA,
- Errante Y,
- et al.
- 13.↵
- 14.↵Drugs@FDA: FDA approved drug products. U.S. Food and Drug Administration. www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Published 2018. Accessed June 14, 2018.
- 15.
- Aime S,
- Caravan P
- 16.↵
- 17.
- 18.↵FDA Drug Safety Communication: FDA warns that gadolinium-based contrast agents (GBCAs) are retained in the body; requires new class warnings [press release]. U.S. Food and Drug Administration. www.fda.gov/Drugs/DrugSafety/ucm589213.htm. Updated May 16, 2018. Accessed January 18, 2019.
- 19.↵Manual on Contrast Media. v.10.3. Reston, VA: American College of Radiology; 2017.
- 20.↵
- Weinmann HJ,
- Brasch RC,
- Press WR,
- Wesbey GE
- 21.↵
- Lauffer RB
- 22.↵
- Caravan P,
- Ellison JJ,
- McMurry TT,
- Lauffer RB
- 23.↵
- Aksoy D,
- Bammer R,
- Mlynash M,
- et al.
- 24.↵
- 25.↵
- Hjort N,
- Wu O,
- Ashkanian M,
- et al.
- 26.
- 27.
- Bastianello S,
- Pozzilli C,
- Bernardi S,
- et al.
- 28.↵
- Stone LA,
- Smith ME,
- Albert PS,
- et al.
- 29.↵Gadoversetamide. Compound summary for CID 444013. National Center for Biotechnology Information. pubchem.ncbi.nlm.nih.gov/compound/444013. Published June 24, 2005. Accessed July 14, 2018.
- 30.↵Gadobutrol. Compound summary for CID 15814656. National Center for Biotechnology Information.pubchem.ncbi.nlm.nih. gov/compound/15814656. Published February 12, 2007. Accessed July 14, 2018.
- 31.↵
- Frenzel T,
- Lengsfeld P,
- Shirmer H,
- Hütter J,
- Weinmann HJ
- 32.↵
- Port M,
- Idée JM,
- Medina C,
- Robic C,
- Sabatou M,
- Corot C
- 33.↵
- Wedeking P,
- Kumar K,
- Tweedle MF
- 34.↵
- White GW,
- Gibby WA,
- Tweedle MF
- 35.↵
- Errante Y,
- Cirimele V,
- Mallio CA,
- Lazzaro VD,
- Zobel BB,
- Quattrocchi CC
- 36.↵
- 37.↵FDA Drug Safety Communication: FDA evaluating the risk of brain deposits with repeated use of gadolinium-based contrast agents for magnetic resonance imaging (MRI). U.S. Food and Drug Administration. www.fda.gov/Drugs/DrugSafety/ucm455386.htm. Published July 27, 2015. Updated May 22, 2017. Accessed January 18, 2019.
- 38.↵
- Kanda T,
- Oba H,
- Toyoda K,
- Furui S
- 39.↵
- 40.↵
- Radbruch A,
- Weberling LD,
- Kieslich PJ,
- et al.
- 41.↵
- Kanda T,
- Fukusato T,
- Matsuda M,
- et al.
- 42.↵FDA Drug Safety Communication: FDA identifies no harmful effects to date with brain retention of gadolinium-based contrast agents for MRIs; review to continue [press release]. U.S. Food and Drug Administration. www.fda.gov/Drugs/DrugSafety/ucm559007.htm. Published May 22, 2017. Updated December 19, 2017. Accessed January 18, 2019.
- 43.↵
- 44.↵
- Cowper SE,
- Robin HS,
- Steinberg SM,
- Su LD,
- Gupta S,
- LeBoit PE
- 45.↵
- Cowper SE,
- Bucala R,
- Leboit PE
- 46.↵
- Altun E,
- Martin DR,
- Wertman R,
- Lugo-Somolinos A,
- Fuller ER,
- Semelka RC
- 47.↵Manual on Contrast Media. v.10.2. Reston, VA: American College of Radiology; 2013.
- 48.↵
- 49.↵
- 50.↵
- 51.↵Consortium of MS Centers MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-up of MS: 2018 Revised Guidelines. Hackensack, NJ: Consortium of Multiple Sclerosis Centers; 2018.
- 52.↵
- 53.↵Consortium of MS Centers MRI Protocol for the Diagnosis and Follow-up of MS. Hackensack, NJ: Consortium of Multiple Sclerosis Centers; 2017.
- 54.↵
- 55.
- 56.↵
- 57.↵
- Rigby PJ
- 58.↵
In this issue
Gadolinium Deposition in Neurology Clinical Practice
Tyler E. Smith, Andrew Steven, Bridget A. Bagert
Ochsner Journal Mar 2019, 19 (1) 17-25; DOI: 10.31486/toj.18.0111